CHRO (Channel Therapeutics) Land And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Land And Improvements?

Channel Therapeutics's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.

Channel Therapeutics Land And Improvements Historical Data

The historical data trend for Channel Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics Land And Improvements Chart

Channel Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Channel Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial										-	-	-	-	-

Channel Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Channel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728

Website

https://www.channeltherapeutics.com

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.